What is it? Why is it important?

A regulatory inspection is a systematic and independent examination conducted by Regulatory Authorities (RA) (e.g. Swissmedic, international).

 

Its purpose is to determine whether a study is conducted according to:

 

The conduct of an inspection follows standarised procedures (e.g. Swissmedic GCP inspection): 

  • Pre-Inspection: inspectors send an announcement letter to the SP-INV, and request documents for review. Inspectors define the inspection plan (e.g. purpose, scope)

 

  • During the inspection: inspectors present the inspection agenda/plan, and proceed to check study documents, perform staff interviews, and a facility tour. Due to a shift in priority, inspectors may decide to adjust the agenda during the inspection. The inspection ends with a closing meeting, where inspection findings are presented

 

  • Post-Inspection: inspectors forward the signed inspection report, assess and approve the CAPA plan of the SP-INV

More

Inspectors can target any establishment involved in the planning and implementation of a study (e.g. the SP-INV, CRO’s, participating study sites, partners).

Based on certain conditions, international RAs may conduct inspections in Switzerland. Foreign inspectors can only access documents related to the scope of the inspection.

What do I need to do?

Prior to an upcoming inspection.....

As a SP-INV:

  • Notify the Site-INV about the upcoming inspection, by providing the site with the inspection agenda (e.g. purpose and scope)
  • Ensure SP-INV documents are current and complete (e.g. filed in the TMF)
  • Initiate inspection pre-trainings, covering roles, responsibilities, dos and don’ts, and how to answer inspectors

 

As a Site-INV:

  • Ensure site documents prove that the study is implemented according to required quality processes (e.g. SOP, WI)
  • Notify study team and ensure documentation shows that the study staff is trained on study responsibilities and quality processes
  • Ensure study site documents are current, complete, filed (e.g. ISF), and readily available during the inspection

 

Post Inspection:

  • Inspectors issue an inspection report describing findings and obligations
  • The study SP-INV provides a written inspection response. The response describes CAPAs, including timeline until when findings are resolved
  • Inspectors review and approve the response rapport, or may request additional adaptations, which must be resubmitted for approval

More

  • Any findings identified during the inspection are documented in an official report issued by RA (e.g. Swissmedic)
  • Findings are categorised according to level of compliance towards RA requirements (e.g. minor , major-, and critical findings according to EMA`s grading of inspection findings)
  • In the event of critical findings, the RA might decide to put participant recruitment on hold, or define further sanctions that must be resolved prior to study continuation

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary: Inspection, Regulatory Authorities
  • 2.3.5 Inspection permission
  • 3.10 Quality management
  • 3.16.4 Record access

ISO 9001 (access liable to costs) – see in particular section

  • QMS Requirements

EMA - see in particular document on

  • Procedures for reporting of GCP inspections requested by the committee for Medical Products for Human Use (CHMP)
  • Appendix 5: Grading of inspection findings

Swiss Law

ClinO – see in particular articles

  • Art. 46 Swissmedic inspections
  • Art. 58 FOPH inspections
Abbreviations
  • CAPA – Corrective and Preventative Actions
  • ClinO – Clinical Trials Ordinance
  • CRO – Contract Research Organisation
  • CTU – Clinical Trials Unit
  • EC – Ethics Committee
  • EMA – European Medicines Agency
  • FOPH – Federal Office of Public Health
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISF – Investigator Site File
  • ISO – International Organization for Standardization
  • RA – Regulatory Authorities
  • Site-INV – Site-Investigator
  • SOP – Standard Operating Procedures
  • SP-INV – Sponsor-Investigator
  • TMF – Trial Master File
  • WI – Working Instruction
Conduct ↦ Quality and Risk ↦ Regulatory Inspections ↦ Conduct
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Quality and Risk ↦ Regulatory Inspections ↦ Conduct